Munich
+49 89 540 31-0 +49 172 8820288 +49 89 540 31-540 s.greifeneder@heuking.de
Languages
German,
English
Practice groups/Expertise
Consulting focuses
- Medicinal Products Law
- Health Care Compliance
- Law on Advertising of Medical Products
- Life Sciences
- Licensing Law
- Medical device regulation
- Pflanzenschutzmittelrecht
- Pharmaceutical Law
- Start-ups
- Commercial Contracts
Vita
- Admitted to the bar since 2004
- Education and former activities
- Partner at Taylor Wessing, Munich (Life Sciences Regulatory)2023-2025
- Partner at Fieldfisher, Munich (Life Sciences)2013-2023
- Counsel at Salans LLP, Frankfurt am Main2012-2013
- Senior Associate at Raupach, Frankfurt am Main2010-2012
- Associate at Ashurst LLP, Munich 2004-2009
- Doctorate degree on „Health and Nutrition claims on Foods“ at Julius-Maximilians-Universität Würzburg2004-2008
- Law studies at Ludwig-Maximilians-Universität Munich1997-2002
- Apprenticeship as banker (IHK) at Bayerische Landesbank, Munich1995-1997
Qualifications/current topics
Stefanie Greifeneder is an expert in regulatory, commercial, and contractual matters in the pharma, medical device, and biotech sectors, as well as in compliance-related topics in this field. She advises on the drafting and negotiation of complex, cross-border license agreements (out-licensing and in-licensing), research and development collaborations, manufacturing and distribution agreements, as well as contracts for clinical trials and with CROs. For M&A and private equity transactions in the life sciences sector, she covers all regulatory and contractual questions.
Affiliations
- International Bar Association (IBA)
Publications
2025
Start of the transition period: EUDAMED use becomes mandatory
Update Health Care & Life Sciences 11/2025,
together with
Sarah Aschenbrenner
Standardisierung als Standortfaktor? Standardvertragsklauseln im Arzneimittelrecht
Platform Life Sciences, Biotechnology Edition 2/2025 p. 70 ff,
together with
Dr. Manja Epping
, Sarah Aschenbrenner
The use of AI in clinical trials
Venture Capital Magazin, Impact Life Sciences, April 2025, p. 14 f.,
together with
Dr. Manja Epping
2024
Forschungskollaborationen von Life-Sciences-Start-ups – Tipps aus der Rechtsberatungspraxis
Plattform Life Sciences, Biotechnology issue 2/2024, p. 78 ff.,
together with
Dr. Manja Epping
Lectures
2025
Finanzierungs- und Exitstrategien für Biotech und Pharma
Finance Day, panel discussion, October 23, 2025, together with Carsten Fietz (c-LEcta), Christopher Guddat (WTS Advisory) and Stefan Maassen (Deutsche Börse), moderated by Markus Rieger (GoingPublic Media)
Änderungen von Arzneimitteln nach der Zulassung, Drug Regulatory Affairs, Zentrum für Weiterbildung und Wissenstransfer (ZWW)
Zentrum für Weiterbildung und Wissenstransfer (ZWW), Drug Regulation, University of Augsburg, October 18, 2025
Vertragsgestaltung in den Life Sciences
Workshop der BioM Biotech Cluster Development GmbH, July 23, 2025, Munich,
together with
Dr. Manja Epping
, Sarah Aschenbrenner